99.7%
filgotinibUCEdinburgh IBD UnitproctitisHerpes Zosterrecombinant zoster vaccination
…ilar era, where cost-effectiveness impacts therapeutic choices, filgotinib is an attractive option for UC. Whilst pivotal trial data and s…
6articles mentioning drugs
15drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Filgotinib ×
Filgotinib
This drug is selected. Its supporting articles are shown below.
Articles mentioning Filgotinib
6 articles · page 1 of 1filgotinibtofacitinibupadacitinibinfliximabadalimumabJAKi
…ents received upadacitinib(47.7%), 15 tofacitinib(34.1%), and 8 filgotinib(18.2%). Thirteen patients (29,5%) received concomitant treatmen…
filgotinibupadacitinibJAKiulcerative colitisCrohn’s diseaseinflammatory bowel diseaseIBDRoyal Free London NHS Foundation Trust
…is. 48 (71.6%) were commenced on upadacitinib and 19 (28.4%) on filgotinib. 32 (47.8%) patients were initiated on treatment prior to, and …
FilgotinibFILUlcerative ColitisNCT05817942
…Background Filgotinib (FIL) is an oral, once-daily, Janus kinase 1 preferential inhib…
upadacitinibtofacitinibfilgotinibbaricitinibJAKirheumatoid arthritisulcerative colitisankylosing spondylitispsoriatic arthritis
… two JAKi, and another 7% have received three. Drugs used were: upadacitinib (40%), baricitinib (35%), tofacitinib (24%), and filgotinib (11…
filgotinibupadacitinibJAKisbaricitinibtofacitinibUPATOFBARFIL
…s; tofacitinib (TOF), baricitinib (BAR), upadacitinib (UPA) and filgotinib (FIL)) in patients with rheumatoid arthritis (RA) in real-world…